Ipamorelin — Apex Research Reference

01 / IDENTITY

Compound Profile

5

AMINO ACIDS

~0.71

kDa MW

SC

ROUTE

~2h

HALF-LIFE

CLASSIFICATION

Synthetic pentapeptide GH secretagogue. Selective agonist of the ghrelin receptor (GHSR-1a) in the pituitary gland. Triggers GH release in a pulsatile, physiological pattern — mimicking the body's natural GH secretion rhythm.

MECHANISM

Binds GHSR-1a on somatotrophs (GH-producing cells) in the anterior pituitary → stimulates GH release. Simultaneously triggers GHRH release from the hypothalamus (amplifying the GH pulse). The GH pulse triggers liver IGF-1 synthesis → downstream anabolic, recovery, and fat-burning effects.

KEY ADVANTAGE

Highly selective — does NOT raise cortisol, prolactin, or ACTH (unlike GHRP-6 and GHRP-2). This selectivity makes Ipamorelin the cleanest GH secretagogue available. Only GH and IGF-1 increase.

VIAL SIZE

10mg lyophilized powder

DEVELOPED BY

Novo Nordisk (Denmark). First disclosed in 1998 — NNC 26-0161. Phase II trials for postoperative ileus. Development halted but compound remains widely available for research.

vs. GHRP-6 / GHRP-2

GHRP-6: raises cortisol + prolactin + appetite significantly. GHRP-2: raises cortisol + prolactin. Ipamorelin: raises GH only. The "cleanest" GH peptide available for sustained use without side effects from cortisol/prolactin elevation.

02 / RESEARCH HISTORY

Development Timeline

1980s

Discovery of GH-releasing peptides (GHRPs) — synthetic compounds that bind a receptor distinct from GHRH receptor to release GH. GHRP-6 (first generation) released GH but also raised cortisol, prolactin, and caused significant hunger. Research direction: find a selective GH secretagogue without these side effects.

1998

Novo Nordisk discloses Ipamorelin (NNC 26-0161) — a pentapeptide with extraordinary selectivity. In head-to-head comparisons, Ipamorelin produces GH release equal to GHRP-6 with zero effect on cortisol, ACTH, or prolactin. Published in Journal of Endocrinology — described as a "highly selective" GH secretagogue. Considered a breakthrough in the field.

2000–2006

Phase I and II clinical trials. Primary indication: postoperative ileus (gut motility restoration) — GH secretagogues stimulate gut motility via ghrelin receptors in the GI tract. Secondary findings confirm profound GH pulse stimulation, improved body composition in elderly patients, and excellent safety and tolerability profile.

2006–2012

Novo Nordisk discontinues Ipamorelin development (business decision, not safety concern) as the postoperative ileus indication didn't achieve regulatory targets. The compound enters the research community with Phase II safety data confirming its clean profile. Anti-aging and performance medicine communities adopt it rapidly.

2012–present

Ipamorelin + CJC-1295 combination becomes the dominant GH optimization protocol in functional medicine, anti-aging clinics, and performance optimization. FDA issues guidance on compounded GHRPs in 2024 — significant clinical use documented across thousands of patients. Considered the gold standard GH peptide protocol.

03 / BENEFITS

Primary Effects

01

Pulsatile GH Release — Physiological Pattern

Ipamorelin stimulates GH release in a sharp, natural pulse — mirroring the body's endogenous GH secretion pattern. This matters: constant GH elevation (as with rhGH injection) desensitizes receptors. Pulsatile GH preserves receptor sensitivity and mimics the GH pattern of a 25-year-old. Each injection produces a GH pulse peaking 30–60 min after injection.

02

Body Recomposition — Fat Loss + Muscle Preservation

GH's primary metabolic effect: lipolysis (fat burning) + lean mass preservation. IGF-1 generated downstream adds anabolic effect on muscle. Net result: simultaneous fat reduction and lean mass increase — true body recomposition. Most pronounced during the 3–6 month continuous use window when GH and IGF-1 levels normalize to younger values.

03

Deep Sleep Enhancement

The largest natural GH pulse occurs during the first slow-wave sleep cycle (60–90 min after sleep onset). Ipamorelin administered before bed amplifies this pulse dramatically. Users consistently report deeper, more restorative sleep — they're actually feeling the enhanced SWS that the amplified GH pulse produces.

04

Recovery Acceleration

GH is the primary driver of protein synthesis in soft tissues — tendons, ligaments, cartilage, and muscle. Elevated GH/IGF-1 dramatically accelerates recovery from training, injuries, and general tissue wear. Users report reduced muscle soreness, faster return to full training after injuries, and improved joint health.

05

Anti-Aging — Restoring Youthful GH Axis

GH production declines ~15% per decade after age 30 (somatopause). By age 60, GH output is 25% of peak. This decline drives: increased visceral fat, decreased lean mass, worse sleep, reduced skin quality, lower energy. Ipamorelin restores GH/IGF-1 to younger ranges without the side effects of exogenous rhGH (no insulin resistance, no joint swelling).

06

Skin Quality & Collagen Synthesis

GH directly stimulates collagen synthesis in skin and connective tissue. Users on long-term Ipamorelin protocols report improved skin thickness, elasticity, and texture. Hair quality improvements also reported. The combination of direct GH skin effects + improved sleep (when sleep is the primary GH boost window) creates compound skin benefits.

04 / RECONSTITUTION

Preparation Protocol

// 10MG VIAL — STANDARD RECONSTITUTION

10,000 mcg ÷ 300 units BAC water = 33.3 mcg per unit

Add 3.0 mL (300 units) bacteriostatic water to 10mg lyophilized vial.

TARGET DOSE	UNITS TO DRAW	VOLUME	NOTE
LOW100 mcg	3 units	0.03 mL	Entry dose; assess GH response
STANDARD200 mcg	6 units	0.06 mL	Most common dose; well-validated
HIGH300 mcg	9 units	0.09 mL	Maximum dose; diminishing returns above 300mcg

Dose Ceiling: GH release from Ipamorelin saturates at approximately 300mcg — doses above this do not produce proportionally higher GH. This is a fundamental difference from CJC-1295, which has a broader dose-response curve. Use 200mcg as the standard target.

Storage: Lyophilized — refrigerate (2–8°C), light-protected. Reconstituted: refrigerate, use within 30 days. Do not freeze reconstituted. Ipamorelin is relatively stable once reconstituted.

05 / DOSING PROTOCOL

Administration Guide

PROTOCOL	DOSE	TIMING	FREQUENCY	CONTEXT
STANDARD	200 mcg SC	Bedtime (fasted)	Daily	Anti-aging, recovery, sleep enhancement
PERFORMANCE	200 mcg SC	2–3× daily: AM, pre-WO, bed	Daily	Body recomp, maximum GH elevation
CJC STACK	200 mcg SC	Bedtime with CJC-1295	Daily	GH pulse + GHRH amplification
COMBINED	200/200 blend	Bedtime fasted	Daily	CJC/IPA blend vial — simplified protocol

The Ipamorelin + CJC-1295 Protocol: This combination is the gold standard GH optimization stack. Ipamorelin (GHSR-1a agonist) + CJC-1295 no DAC (GHRH analog) = two independent mechanisms acting simultaneously → synergistic GH pulse amplitude 2–4× higher than either alone. The blend vial makes this even more convenient.

06 / TIMING

Administration Timing

CRITICAL — FASTED STATE

Must be injected in a fasted state — minimum 2 hours after last meal. Elevated insulin (from food) directly inhibits GH release at the pituitary level. Insulin is GH's "off switch." Fasted injection = maximal GH pulse. Bedtime (3+ hours after dinner) is the ideal window.

BEDTIME DOSING

Primary protocol. Amplifies the natural GH pulse that occurs during first SWS cycle. Sleep onset → SWS → GH pulse amplified by Ipamorelin → deeper sleep, better recovery. Most efficient use of a single daily dose.

MULTI-DOSE TIMING

For 2–3× daily protocols: Morning fasted (before breakfast), pre-workout (1.5h post meal), and bedtime. Each injection window should be 2+ hours fasted. Morning + bedtime is the most practical 2× protocol.

POST-INJECTION WAIT

Wait 30–60 minutes after injection before eating following bedtime dose (to capture peak GH pulse during the fasted window). Don't eat after injecting until the pulse has occurred.

07 / BIOMARKERS

Monitoring Panel

// GH AXIS MARKERS

MARKER	TEST	CLINICAL RANGE	OPTIMAL ON IPAMORELIN
IGF-1GH Axis Proxy (Best Test)	AM fasting serum draw	CLINAge-dependent (20s: 115–307 ng/mL)	OPTUpper-normal for age (200–300 ng/mL for adults) — primary efficacy marker
GH (Random)Growth Hormone	Serum (timing-sensitive)	CLIN0–10 ng/mL (random; highly variable)	NOTEIGF-1 is the better test — GH is pulsatile and timing-dependent
IGFBP-3IGF Binding Protein	Serum	CLIN1.6–6.1 mg/L (adults)	OPTUpper-normal range (IGFBP-3 rises proportionally with IGF-1)

// BODY COMPOSITION & METABOLIC

MARKER	TEST	CLINICAL RANGE	EXPECTED IMPROVEMENT
DEXA ScanBody Composition	DEXA (pre + 3 month + 6 month)	CLINBaseline measurement	OPTReduced fat mass, maintained/increased lean mass over 3–6 months
Fasting GlucoseGH-Insulin Interaction	Standard lab	CLIN70–99 mg/dL	NOTEMonitor — GH can induce mild insulin resistance in some users. If FBG rises, reduce dose or frequency.
Cortisol (AM)Selectivity Confirmation	AM serum	CLIN6–23 mcg/dL	NOTENO CHANGE expected — confirms Ipamorelin's selectivity (vs. GHRP-6/2 which raise cortisol)

08 / CYCLE PROTOCOL

Recommended Cycle

3–6

MONTHS ACTIVE

Daily

FREQUENCY

4–8

WEEKS OFF

Bedtime

INJECTION TIME

Months 1–3 (Foundation): 200mcg SC bedtime daily, fasted. IGF-1 levels begin rising within 2–4 weeks. Body composition changes (fat loss, improved muscle tone) typically visible by month 2. Sleep quality improvement usually noticed within 1–2 weeks.

Months 3–6 (Optimization): Continue 200mcg bedtime. Add 200mcg morning dose if accelerated body recomposition is desired. Measure IGF-1 at month 3 — adjust dose if IGF-1 hasn't reached upper-normal range for age.

Off Period: 4–8 weeks off after 3–6 month cycle. Pituitary sensitivity resets. Many anti-aging practitioners run 5 months on / 1 month off continuously — a reasonable long-term protocol supported by the compound's safety profile.

Gold Standard Stack: Ipamorelin 200mcg + CJC-1295 no DAC 200mcg SC at bedtime fasted. This combination produces 2–4× the GH pulse amplitude of either alone. Add DSIP 250mcg for maximum sleep architecture optimization. This bedtime protocol is the cornerstone of any serious anti-aging or recovery optimization program.

Research Compound Notice: Ipamorelin has completed Phase II clinical trials (Novo Nordisk, 2006). It has not been approved by the FDA. The clinical data demonstrates excellent safety with zero cortisol, prolactin, or ACTH effects — superior safety profile to older GH secretagogues. Not for use in active cancer (GH promotes growth). Monitor fasting glucose with long-term use. Consult a qualified healthcare provider before starting any GH axis optimization protocol.